Clinical Study

S1931-Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)

Posted Date: May 5, 2021

  • Investigator: Robert Franklin
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The main objective of this study is to compare the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). The primary outcome measure is overall survival.


Participants Must Have A Histologically Proven Diagnosis Of Clear Cell Or Non-Clear Cell Renal Cell Carcinoma, Zubrod Performance Status Of 0-1, Treatment Naive Participants Must Have Scans Documenting Metastatic Disease Completed Within 90 Days Prior To Study Registration, Stable Disease. No Active Brain Metastases, No Kidney Transplant, No Other Malignancy Within 2 Years.


Kidney Cancer, Renal Cell Carcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.